July 2014 Volume 10, Issue 7
Volume 10, Issue 7 | July 2014
July 2014
In this Issue
Business & Government Policy
Merck makes big HCV move with Idenix deal
$3.85-billion acquisition aims to expand Merck’s hepatitis pipeline and dethrone GileadHikma to purchase Bedford Laboratories, Ben Venue site
Acquisition may lead to re-launch of several Bedford productsVentrus Biosciences to merge with Assembly Pharmaceuticals
Combined company will focus on developing Assembly’s first-in-class small molecules for hepatitis B treatmentPatent Docs - Meeting Recap: BIO 2014 International Convention highlights
Patent Office guidelines, as well as Mayo and Myriad cases, loomed large for presenters, attendeesGut reaction
Takeda’s Entyvio gets FDA and EU approval for ulcerative colitis and Crohn’s diseaseEpigenomics provides update on Epi proColon in the U.S.
Recent meeting between the company and the FDA involved detailed discussions regarding the design of upcoming clinical studyResearch & Development
T cells against cancer
Adaptimmune and GSK collaborate on $350-million oncology-oriented immunotherapy pactBMS looks to Probodies for select cancer targets
Bristol-Myers Squibb strikes deal with CytomX Therapeutics worth up to $348 millionHaving a go at HER2
The recent discovery of a link between protein PTP1B and HER2 could provide a new therapeutic targetOhr acquires assets from SKS Ocular
Ohr Pharmaceutical to pay $3.5 million up front for tech platform and preclinical candidatesTrying to head off cancer
Antitope and BIIR to work on cell line for novel therapeutic dendritic-cell-targeting vaccinePreclinical
A call for balance
NIH to require grant applicants to report cell, animal sexes in preclinical studiesA Cambridge combination
Horizon to acquire Zalicus’ CombinatoRx business and assets for $8 millionFrom intoxication to ADHD
Alcobra presents results showing new potential for MDX as treatment for cognitive disordersSeeing the whole picture
Imaging system offers view of complete nervous systemTurning T cells on … and off
Inovio Pharmaceuticals acquires early-stage DNA therapies to treat Alzheimer’s and multiple sclerosisSpecial Reports
Special Report on Cell Biology: Life moves on
Physics, chemistry and informatics combine to push life into the 4th dimensionQ&A
Q&A: In Parkinson’s disease, a new treatment for ‘off’ periods
DDNews talks with Anthony Giovinazzo of Cynapsus Therapeutics about his company's drug candidate, APL-130277, an easy-to-administer, fast-acting reformulation of apomorphineEditor's Focus
Keeping in touch with all of you
As we move into summer and I've settled more comfortably into the chief editor's chair, it's time to step up our social media activity, and to let you know about our new Facebook pageCommentary
Out of Order: Modestly modeled
Randall C Willis talks about what's wrong with the disease models we currently use to discover and develop therapeutics and points us in the general direction of where we need to go to get models more in line with realityCommentary: Personalized medicine--Bridging the gaps
Current and emerging technologies capable of providing person-specific data far outpace the ability to effectively mine that data to draw clinical conclusions and develop clinically relevant productsDiagnostics
A companion for Revlimid
NanoString inks $45-million deal to develop diagnostic test for Celgene drugAgena Bioscience acquires Sequenom unit
Deal to expand Agena’s diagnostic market and advance its UltraSEEK technology is worth $35.8 millionFrom biopsies to blood-based testing
Merck Serono, Sysmex Inostics seek a blood-based RAS biomarker test for colorectal cancer patientsCancer Genetics partners with AstraZeneca
Agreement on biomarker and molecular-based testing expands reach of Cancer Genetics’ servicesClinical Trials
Merrimack touts four at 2014 ASCO
Planning underway for Phase 2 studies for MM-151 in colorectal cancer and MM-141 in front-line pancreatic cancerApproval hopes for IPF therapy ASCEND
InterMune resubmits pirfenidone lung disease drug to FDA after more stringent trialPlaque attack
Amgen and AstraZeneca announce positive results from Phase 3 study of brodalumab for moderate to severe plaque psoriasisNektar makes progress against glioma
Phase 2 study shows NKTR-102 to have better-than-expected results against common brain cancerDiscovery
Antibodies anyone?
MorphoSys and Temple University partner for therapeutic antibody discoveryTracking the life cycle of a single cell
Microchip-like technology allows single cell analysisNailing down Env in HIV
TSRI research details newly discovered binding sites for HIV antibodiesA new molecule to treat asthma
Study identifies a novel molecule that prevents the symptoms associated with allergen-induced asthma
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Harnessing liver-on-a-chip models for drug safety
Discover how researchers leverage microphysiological systems in toxicology studies.
Enhancing bioanalytical studies with centralized data management
Learn how researchers can improve compliance and efficiency with advanced LIMS solutions.
Explained: How are metabolite biomarkers improving drug discovery and development?
By offering a rich source of insights into disease and drugs, metabolite biomarkers are at the forefront of therapeutic exploration.
